MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
"Triple Helix" Innovation Model
3. Triple Helix _ Dynamics
*Driving Forces: Triple Helix _ Translation, Commercialization, Technology Transfer, SBIR/STTR, OTA, NonTraditional / New Business Models
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Research Triangle, North Carolina
Tranzyme Pharma
Parents
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
*Industry: North Carolina
*Industry: Research Triangle, North Carolina
*Portfolio Companies: Quaker BioVentures
Business Development Bank of Canada -(#6, 24 Deals 2005)
H.I.G. Ventures
Pacific Rim Venture Partners
Portfolio Companies: Thomas, McNerney
Children
Dr David Drutz, M.D., Chairman of Tranzyme Pharma and General Partner, Pacific Rim Ventures
Dr Vipin Garg, Ph.D., President and Chief Executive Officer of Tranzyme Pharma
Durham drug maker files for $75M IPO
Lead product, TZP-101, is expected to enter clinical trials for the treatment of post-operative ileus before the end of 2005
Novel mechanism-based therapeutics for the treatment of gastrointestinal (GI) disorders
Research Triangle, North Carolina
The Company also has novel small molecule compounds in its preclinical pipeline for diabetic gastroparesis, irritable bowel synd